Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Outgoing FDA Commissioner Proposes Expedited Steps for Approval of CBD
insert-text-here
I think you are right - article on short attack: hinsert-text-here
Yeah - I don't see any material weakness in the company. My thesis still holds and so do I. I usually enter into positions with a 3 year time frame. I got 32 months left - so not sweating it!
Algo short attack. Same as most of the companies in this sector.
Low volume.. shares are moving from impatient to patient hands imo
Never could understand people selling at support levels instead of buying.
They seem to be down a little bit more than most of my watchlist and I haven't seen any bad news so I figured I would ask. This stock has always moved a little unusual anyways.
Everything seems to be ok - not sure why the price is under pressure.
What is going on with this stock? Have this on my watchlist and have been following the price for a year. Did I miss some news?
Maybe it needs to fill the silly gap at 1.83 from the beginning of the year ;)
Agree, but thinkin CWEB wakens the cbd group. Main reason I’m playin here at this level
Those potentially could be tailwinds, but in the US this is a very crowded space and Elixinol may struggle to maintain or grow their market share specifically in the US due to the sheer amount of competition they face here and their international strategy. I will say as well that I'm not too optimistic on FDA actions regarding CBD given their current stance. It's dangerous to speculate on this stuff, and one of the main reasons I'm long on Elixinol is because their focus on growth in Europe and elsewhere outside of the US should provide somewhat greater stability than companies focused solely on NA markets. Sector-wide, I just don't see the same optimism as before and I doubt Elixinol can stage a sustained move higher in the near-term as a result. Look at the price action since the Q1 disappointment... very choppy, but also very downbeat--just like most others in the sector.
CBD is still projected to hit $5billion this year.. even if it does $3 billion Elixonol should benefit as long as they’re capturing some of the US market. With fda pathways for cbd coming we should see some upward momentum from down here
Last two quarterlies have been extremely weak. Sentiment is going to be consistently pessimistic as long as this is the case and it's unlikely ELLXF can follow broader sector rallies. That's why we're down 50% from ATHs instead of rallying strongly back toward highs like certain other stocks in this space. Nothing to preclude a short-term pop near oversold levels right now, but the days of cannabis companies managing to maintain insane valuations and rally on weakness are over. The sector is returning to reality and so is ELLXF. Best case as I see it is extreme chop until Q3 earnings... if top line growth accelerates a bit and they don't burn as much cash, maybe a more sustainable rally toward previous levels can occur. For now, I'm not seeing it, personally.
surely the lift in weed stocks will help the CBD laggards as well. unless there's something independently wrong with Elixinol that I'm missing I'd say we're in a loading zone.. here or lower, should bounce back.
Nice little awakening today. Hopefully won’t have to close eyes and buy lower.. I suppose 2.20 is the area it’ll need to pop through
to convince me
Fibs point to a range between 1.90s to 1.75ish so might need to come down a bit more first. Not sure what to think about the newsletter’s issues with IR but I guess I’ll just ignore that part. Lol
I agree - a great spot to load.
Same here.. just added some low 2s..
I think current selling pressure could be from Cannabis Investor's email that announced putting ELLXF on Hold yesterday.. simply because the guy who runs it had some questions regarding company and haven't received answers right away from them lol that may have spooked some folks.. whatever..
ELLXF trades very thin, little update and momo and it will test $3 on air imo
Opportunity to buy up, imo
someone let ELLXF know whats goin on. i think she's asleep still
We may see a general sector rally for marijuana etc today post Aphria earnings report.
All of you need to see this blatant fraud: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150279741
I don't know anymore, man... I've been long on this (and CWBHF) since December, but the outlook has worsened severely and I'm not sure there will be much of a short-term bounce here, even with how Charlotte's Web is rallying right now. The quarterlies were just bad, really. Revenue growth still lagging, massive cash burn... it's hard to envision any big rally here in the wake of disappointing results. Long-term is also questionable, they'd have to experience massive revenue growth to achieve any sort of sustainability--not enough cash to sustain this for more than a year or so. I'm still holding, but as I see it things have deteriorated quite a bit. Good luck.
Grabbed some here along with CWEB momo.. leaving room to add if it does 1.90s but ideally a run from here
Elixinol and PharmaCare Release New Hemp CBD Capsules
https://www.globenewswire.com/news-release/2019/08/01/1895629/0/en/Elixinol-and-PharmaCare-Release-New-Hemp-CBD-Capsules.html
TV Ads UK (Naturopathica+) insert-text-here
We're on the same page. That was my conclusion also.
If I can interject, I interpret it as meaning that the low margin products are a drag on the results so they are shifting their resources away from them.
The way I interpret it is that there results would have been higher, if they weren't focusing on shifting the biz focus to higher margin brand products. I think they were willing to accept a lower quarter of results, expecting better results down the road post shift. That's how I see it currently. What do you think?
Pan O War, what does that paragraph mean exactly?
I think they have managed to shift the baseline of how they are operating, their focus, production capacity and how/where they are selling. I think growth will pick-up from here:
"In the Company’s March 2019 quarterly update, it communicated its strategic decision to
reduce focus on lower margin private label business in the US to enable increased capacity
for expected future growth of higher margin branded products and provide the ability to capture
further market share. Excluding this private label business, normalised revenue growth for Q2
FY2019 would have been reported at 38% on PCP (normalised revenue growth for H1 FY2019
would have been reported at 34% on PCP)."
Excellent - love that we are a global player, and not just USA.
Elixinol partners with PharmaCare to release CBD products
ASX Announcement 29 July 2019
https://www.elixinolglobal.com/site/PDF/2557_0/ElixinolpartnerswithPharmaCare
Video review of Elixinol Products: insert-text-here
Added with size today.
CBD, some companies are doing it well....
Elixinol is one of em.
These cheapies are too good to pass up.
Seems like a stock specific panic on no news. ELLXF makes no claims - so not in the same boat as Curaleaf.
Is this continued drop accelerating from FDA debate hearing and Cura problems earlier this week? Other CBDs have started to hold and reverse. Thoughts on Elixinol’s advantages and challenges?
Video - Paul at Irish Hemp Summit: insert-text-here
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |